Keyphrases
Ceftolozane-tazobactam
100%
Resistance Type
100%
Escherichia Coli Isolates
100%
Sequence Type 131
100%
Co-resistance
100%
Escherichia Coli
71%
Meropenem
42%
Levofloxacin
28%
Fluoroquinolone Resistance
28%
Ceftazidime
28%
Fluoroquinolones
28%
Antimicrobial Resistance
14%
Multidrug Resistance
14%
Gentamicin
14%
Veterans Affairs Medical Center
14%
Carbapenems
14%
C(T)
14%
Resistant Isolate
14%
Resistance Prevalence
14%
Multidrug-resistant E. Coli
14%
Extended-spectrum β-lactamase
14%
Inhibitor Agent
14%
Broth Microdilution
14%
Gentamicin-resistant
14%
β-lactamase Inhibitor
14%
Resistant Spectrum
14%
Carbapenem-sparing
14%
Extended-spectrum beta-lactamase-producing
14%
Medicine and Dentistry
Escherichia coli
100%
Ceftolozane
100%
Tazobactam
100%
Quinolone Derivative
50%
Meropenem
37%
Infection
25%
Extended Spectrum Beta Lactamase
25%
Levofloxacin
25%
Ceftazidime
25%
Carbapenem
25%
Gentamicin
25%
Antiinfective Agent
12%
Prevalence
12%
Veterans Affairs
12%
Multidrug Resistance
12%
β-Lactamase inhibitor
12%
Beta Lactamase Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Escherichia coli
100%
Tazobactam
100%
Ceftolozane
100%
Quinolone Derivative
50%
Meropenem
37%
Gentamicin
25%
Infection
25%
Ceftazidime
25%
Extended Spectrum Beta Lactamase
25%
Carbapenem
25%
Levofloxacin
25%
Antiinfective Agent
12%
Prevalence
12%
Beta Lactamase Inhibitor
12%
Multidrug Resistance
12%
Biochemistry, Genetics and Molecular Biology
Escherichia coli
100%
Tazobactam
100%
Minimum Inhibitory Concentration
42%
Beta-Lactamase
42%
Ceftazidime
28%
Levofloxacin
28%
Gentamicin
28%
Broth Dilution
14%
Prevalence
14%
Multidrug Resistance
14%
Immunology and Microbiology
Escherichia coli
100%
Minimum Inhibitory Concentration
42%
Prevalence
14%
Multidrug Resistance
14%
Broth Dilution
14%